☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Merus
Merus Reports the First Patient Dosing in P-III (LiGeR-HN1) Study of Petosemtamab Plus Keytruda for 1L Treatment of R/M Head and N...
October 1, 2024
Merus’ Petosemtamab Receives the US FDA’s Breakthrough Therapy Designation for Head and Neck Squamous Cell Carcinoma
May 14, 2024
Merus Highlights the Preclinical Results from the Study of Zenocutuzumab for Cancer Treatment at the AACR 2024
April 9, 2024
Merus and Gilead Enter into a Research Collaboration, Option & License Agreement to Discover of Antibody-Based Trispecific T-Cell...
March 7, 2024
Merus’ Zenocutuzumab Receives the US FDA’s Breakthrough Therapy Designation for NRG1 Fusion Non-Small Cell Lung Cancer
July 6, 2023
PharmaShots Weekly Snapshots (Jan 18 - 22, 2021)
January 22, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.